Furthermore, decitabine, which is a methyltransferase inhibitor similar to azacitidine, was shown to increase CD19 expression on B-cell lymphoma cell lines without impairing CAR-T-cell functionality [20] (Figure 1). The gene discussed is CD19; the disease is B-cell non-Hodgkin lymphoma.